PharmAla Biotech

03/11/2025

PharmAla is pleased to announce it has filed its final short-form base shelf prospectus, enabling flexible financing over the next 25 months.

31/10/2025

From the desk of Nick Kadysh, Founding CEO, PharmAla Biotech,

CEO Letter to Shareholders.

23/10/2025

“For the first time in 15 years, I felt peace.”

After years of depression, suicidal thoughts, and disconnection, veteran Josh Vino found healing through psychedelic-assisted therapy.

He’s now calling on Canada to act:
“A solid move in this direction will save lives. The time is now.”

22/10/2025

Today, PharmAla Biotech CEO, Nick Kadysh, joined PsyCan alongside military veterans in Ottawa to urge the Canadian government to remove barriers and make life saving therapies more accessible. Urgent change is needed as the number of Canadians suffering from mental health disorder rises.

15/10/2025

Join us Wednesday October 22nd, at 4PM EST for a deep dive into our new NEXUS Prescriber’s Portal.

Speakers will:

* Showcase new and improved features
* Share best practices for seamless integration
* Introduce our upgraded customer support experience

This session is an excellent opportunity to explore the full capabilities of the Nexus Portal, ask questions, and get insider tips directly from our team.

This webinar is open exclusively to licensed medical professionals within our Prescribers’ Portal. Join our NEXUS Portal below to receive your invite.

08/10/2025

PharmAla is pleased to announce the launch of NEXUS, its new and updated tool to bring together and connect Prescribers, Therapists and Clinic managers.

25/09/2025

PharmAla is pleased to announce that it has signed an agreement with Veridion Group to act as its distribution partner in New Zealand.

New Zealand’s Medsafe agency recently approved the first authorized psychiatrist allowed to treat patients with Psilocybin, and several applications are underway for authorization to implement M**A-Assisted Therapy for PTSD.

08/09/2025

PharmAla is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.

Press Release: https://pharmala.ca/media/2025/09/pharmala-completes-import-of-laneo-mdma-for-u-s-distribution

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.

08/09/2025

Will Avery, PharmAla Biotech CFO, highlights key financial milestones: FY24 revenue up 95% to $1 M+; resumed SAP shipments in Canada & the U.S.; expanded clinical trial deliveries via a new U.S. distributor; and raised $1.5 M+ through Q3 ’25.

03/09/2025

PharmAla is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. , a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.

Press release: https://pharmala.ca/media/2025/09/pharmala-incorporates-australian-entity-for-clinical-research

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.

10/06/2025

See you in Denver! We are proud to be speaking at , the largest psychedelic conference of its kind! Join MAPS from June 16-20 for Psychedelic Science 2025 at the Colorado Convention Center in Denver, Colorado. Featuring educational stages, an immersive expo hall, workshops, and community— you do not want to miss the integration!